(VIANEWS) – Natural Health Trends Corp. (NHTC), Pfizer (PFE), Western Asset High Income Fund II (HIX) are the highest payout ratio stocks on this list.
We have congregated information regarding stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Natural Health Trends Corp. (NHTC)
2000% Payout Ratio
Natural Health Trends Corp., a direct-selling and e-commerce company, provides personal care, wellness, and lifestyle products under the NHT Global brand. The company offers wellness products, including liquid, encapsulated, tableted, and powder dietary and nutritional supplements, as well as vitamins and minerals; and herbal products comprising herbal supplements. It also provides beauty products, such as age-defying and hydrating cleansers, creams, lotions, serums, and toners; and lifestyle products, which include weight management and energy enhancing supplements. In addition, the company offers home appliances; daily products, such as oral care, hair care, and body care; and home appliances products. It sells its products directly to consumers, as well as through an e-commerce retail platform in the United States, Canada, Cayman Islands, Mexico, Peru, Hong Kong, Taiwan, China, Singapore, Malaysia, Thailand, Vietnam, South Korea, Japan, India, Russia, Kazakhstan, and Europe. The company was formerly known as Florida Institute of Massage Therapy, Inc. and changed its name to Natural Health Trends Corp. in June 1993. Natural Health Trends Corp. was incorporated in 1988 and is headquartered in Tsim Sha Tsui, Hong Kong.
Earnings Per Share
As for profitability, Natural Health Trends Corp. has a trailing twelve months EPS of $0.04.
PE Ratio
Natural Health Trends Corp. has a trailing twelve months price to earnings ratio of 132.01. Meaning, the purchaser of the share is investing $132.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.84%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 9.4%, now sitting on 45.5M for the twelve trailing months.
Yearly Top and Bottom Value
Natural Health Trends Corp.’s stock is valued at $5.28 at 16:23 EST, way below its 52-week high of $7.04 and way higher than its 52-week low of $3.40.
Moving Average
Natural Health Trends Corp.’s worth is under its 50-day moving average of $5.42 and under its 200-day moving average of $5.44.
2. Pfizer (PFE)
89.07% Payout Ratio
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Pfizer has a trailing twelve months EPS of $1.83.
PE Ratio
Pfizer has a trailing twelve months price to earnings ratio of 15.66. Meaning, the purchaser of the share is investing $15.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 8, 2023, the estimated forward annual dividend rate is 1.64 and the estimated forward annual dividend yield is 5.7%.
Moving Average
Pfizer’s value is under its 50-day moving average of $30.94 and way under its 200-day moving average of $36.02.
Sales Growth
Pfizer’s sales growth is negative 40.7% for the ongoing quarter and negative 6.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 114.9% and a negative 30.1%, respectively.
Previous days news about Pfizer (PFE)
- Pfizer's (pfe) multiple myeloma drug elrexfio gets nod in EU. According to Zacks on Monday, 11 December, "Shares of Pfizer have declined 43.8% so far this year against the industry’s increase of 4.3%."
- : Pfizer expects to close seagen deal on Thursday, will create a new oncology division to incorporate company. According to MarketWatch on Tuesday, 12 December, "The company will create an end-to-end business organization called the Pfizer Oncology Division, which will combine certain commercial and R&D operations from both companies. "
- Pfizer's (pfe) hemophilia candidate BLA gets FDA acceptance. According to Zacks on Tuesday, 12 December, "Other than marstacimab, Pfizer has developed two other investigational gene therapies for hemophilia patients - fidanacogene elaparvovec (for hemophilia B) and giroctocogene fitelparvovec (for hemophilia A). "
- According to GlobeNewsWire on Tuesday, 12 December, "Per the announcement by Pfizer Inc. (NYSE: PFE), the pending acquisition of Seagen, Inc. (Nasdaq: SGEN) is expected to close on December 14, 2023. "
3. Western Asset High Income Fund II (HIX)
76.36% Payout Ratio
Western Asset High Income Fund II Inc. is a closed-ended fixed income mutual fund launched and managed by Legg Mason Partners Fund Advisor, LLC. The fund is co-managed by Western Asset Management Company, Western Asset Management Company Limited, and Western Asset Management Company Pte. Ltd. It invests in the fixed income markets across the globe. The fund invests in securities of companies that operate across diversified sectors. It invests in high yield debt securities issued by U.S., foreign corporations and foreign governments. The fund employs a combination of quantitative and fundamental analysis with bottom-up security selection process to create its portfolio. It benchmarks the performance of its portfolio against Barclays Capital U.S. Corporate High Yield 2% Issuer Cap Index and the JPMorgan Emerging Markets Bond Index Global. Western Asset High Income Fund II, Inc. was formed on May 28, 1998 and is domiciled in the United States.
Earnings Per Share
As for profitability, Western Asset High Income Fund II has a trailing twelve months EPS of $-0.48.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.26%.
Yearly Top and Bottom Value
Western Asset High Income Fund II’s stock is valued at $4.75 at 16:23 EST, way below its 52-week high of $5.71 and way above its 52-week low of $4.16.
4. Interpublic Group of Companies (IPG)
51.05% Payout Ratio
The Interpublic Group of Companies, Inc. provides advertising and marketing services worldwide. The company operates through two segments, Integrated Agency Networks and Constituency Management Group. The company offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines, as well as data management services. It also provides various diversified services, including meeting and event production, sports and entertainment marketing, corporate and brand identity, and strategic marketing consulting. The company was formerly known as McCann-Erickson Incorporated and changed its name to The Interpublic Group of Companies, Inc. in January 1961. The Interpublic Group of Companies, Inc. was founded in 1902 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Interpublic Group of Companies has a trailing twelve months EPS of $2.39.
PE Ratio
Interpublic Group of Companies has a trailing twelve months price to earnings ratio of 13.1. Meaning, the purchaser of the share is investing $13.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.3%.
Sales Growth
Interpublic Group of Companies’s sales growth is 0.3% for the current quarter and 0.2% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 29, 2023, the estimated forward annual dividend rate is 1.24 and the estimated forward annual dividend yield is 3.96%.
5. Patterson Companies (PDCO)
50.73% Payout Ratio
Patterson Companies, Inc. engages in distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.
Earnings Per Share
As for profitability, Patterson Companies has a trailing twelve months EPS of $2.05.
PE Ratio
Patterson Companies has a trailing twelve months price to earnings ratio of 12.97. Meaning, the purchaser of the share is investing $12.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.04%.
Volume
Today’s last reported volume for Patterson Companies is 863223 which is 16.32% below its average volume of 1031640.
6. Atmos Energy Corporation (ATO)
48.52% Payout Ratio
Atmos Energy Corporation, together with its subsidiaries, engages in the regulated natural gas distribution, and pipeline and storage businesses in the United States. It operates in two segments, Distribution, and Pipeline and Storage. The Distribution segment is involved in the regulated natural gas distribution and related sales operations in eight states. This segment distributes natural gas to approximately three million residential, commercial, public authority, and industrial customers. As of September 30, 2020, it owned 71,558 miles of underground distribution and transmission mains. The Pipeline and Storage segment engages in the pipeline and storage operations. This segment transports natural gas for third parties and manages five underground storage reservoirs in Texas; and provides ancillary services to the pipeline industry, including parking arrangements, lending, and inventory sales. As of September 30, 2020, it owned 5,684 miles of gas transmission lines. Atmos Energy Corporation was founded in 1906 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Atmos Energy Corporation has a trailing twelve months EPS of $6.1.
PE Ratio
Atmos Energy Corporation has a trailing twelve months price to earnings ratio of 18.66. Meaning, the purchaser of the share is investing $18.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 18.7%, now sitting on 4.28B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 8.4% and 6%, respectively.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 23, 2023, the estimated forward annual dividend rate is 3.22 and the estimated forward annual dividend yield is 2.83%.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Sales Growth
1’s sales growth is 1% for the present quarter and 1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
1’s EBITDA is 1.
